Previous Article | Next Article 
J Virol, July 1998, p. 6175-6180, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Woodchuck Hepatitis Virus Enhancer I and Enhancer
II Are Both Involved in N-myc2 Activation in Woodchuck
Liver Tumors
Marc
Flajolet,
Pierre
Tiollais,
Marie-Annick
Buendia, and
Geneviève
Fourel*
Unité de Recombinaison et Expression
Génétique, INSERM U163, Institut Pasteur, 75724 Paris Cedex
15, France
Received 8 December 1997/Accepted 25 March 1998
 |
ABSTRACT |
Direct activation of the N-myc2 oncogene by insertion
of woodchuck hepatitis virus (WHV) DNA is a major oncogenic step in woodchuck hepatocarcinogenesis. We previously reported that WHV enhancer II (We2), which controls expression of the core/pregenome RNA,
can also activate the N-myc2 promoter in hepatoma cell
lines. To better define the integrated WHV regulatory sequences
responsible for N-myc2 promoter activation in woodchuck
liver tumors, we analyzed the structure and enhancer activity of a
single viral integrant found at the win locus in tumor
2260T1 and mapping approximately 175 kb 3' of N-myc2. This
viral insert was made of 11 concatemerized WHV fragments, 5 of which
overlapped with We2 sequences and 1 with WHV sequence homologous to
that of hepatitis B virus enhancer I (We1). In transient transfection
assays in hepatoma-derived cells, the We2 activator was found to be
fully effective only when inserted in close proximity to the
N-myc2 promoter whereas the We1 element by itself was
apparently devoid of activity. In contrast, the 2260T1 viral insert
exhibited a potent enhancer capacity that depended both on multimerized
We2 and on We1 sequences. In a survey of different woodchuck hepatomas,
both elements were commonly found within integrated viral sequences
involved in long-range N-myc2 activation.
 |
TEXT |
Hepatocellular carcinoma, one of the
most frequently occurring human cancers worldwide, is commonly
associated with chronic infection by hepatitis B virus (HBV). The
incidence of hepatocellular carcinoma is 100-fold higher among HBV
carriers than in uninfected populations (2). Two closely
related viruses of the hepadnavirus family, woodchuck hepatitis virus
(WHV) and ground squirrel hepatitis virus, similarly increase the risk
of liver cancer development in their hosts (17, 24) and thus
provide suitable model systems. WHV displays an especially strong
oncogenic capacity. Virtually all animals infected with WHV at birth
succumb to liver cancer within 2 to 4 years, whereas noninfected
woodchucks rarely develop spontaneous malignancies over a period of 10 years (20). cis activation of myc
family oncogenes due to the insertion of viral DNA is known to be the
key mechanism of woodchuck hepatocarcinogenesis (for reviews, see
references 3 and 9). Indeed, a
majority of woodchuck liver tumors harbor viral sequences integrated in the immediate vicinity of either c-myc or N-myc
or, more frequently, in N-myc2 (a functional retroposon) as
well as in the win locus, which maps 155 to 185 kb
downstream of N-myc2 (10, 11, 14). These viral
insertions correlate with activation of transcription from the normal
promoter of the target myc gene, implying the cis
action of integrated viral regulatory elements over short as well as
long distances. Furthermore, hepatocarcinogenesis is recapitulated in
transgenic mice carrying such an altered c-myc or
N-myc2 allele (7, 21). The viral regulatory
elements involved in the up-regulation of N-myc2 expression
were previously examined by transient transfection assays of different
liver cell lines (5, 12, 27, 31). WHV sequences
corresponding in position to enhancer I of HBV (We1) appeared devoid of
activity on their own. By contrast, sequences corresponding to enhancer
II (We2) strongly activated expression in an orientation-independent
but position-dependent manner. We2 activity was shown to result
primarily from the synergistic function of one binding site for the
liver-enriched HNF1 protein and two sites for the HNF4 protein,
although NF-1 and Oct family members were also shown to bind in a
central region (12, 28). In those studies, however, WHV's
cis-activation capacity was dissected through the in
vitro-engineered juxtaposition of various portions of the cloned WHV
genome with different promoters. To identify WHV regulatory elements
genuinely involved in N-myc2 oncogene activation during
hepatocarcinogenesis in the animal, we used another approach, one more
relevant to carcinogenesis: analysis of a naturally occurring viral
integrant mapping at the win locus with regard to its
structure and cis-activation capacity.
The single integrant from the 2260T1 tumor was preliminarily described
in a previous report (11). A library enriched by size
selection of BglII-digested 2260T1 DNA was constructed in the phage vector
-GEM11 (Promega), and WHV-hybridizing clones were
isolated. Restriction mapping of the phage inserts confirmed the
insertion of an approximately 3-kb-long WHV sequence in cellular DNA
without any additional recombination of the win locus, as previously inferred from Southern blot analysis. A 4.3-kb
SmaI-HindIII fragment encompassing the viral
insertion was further subcloned into the SmaI site of the
pKS+ vector (Stratagene). The structural organization of the integrated
WHV DNA was tentatively determined by restriction mapping and Southern
blot hybridization with subgenomic WHV probes. However, it was
difficult to recognize any restriction pattern characteristic of the
WHV genome, with the exception of the bordering segments (Fig.
1A). The one indicated as the 5' end
corresponded to the region extending from positions 1150 to 1950 on the
viral map (with nucleotide numbering as in reference 15), spanning sequences homologous to HBV enhancers
I and II, and the 3' end mapped to the 3' region of the S gene
(positions 400 to 900). Because this initial analysis suggested that
there were complex rearrangements in the integrated viral DNA, the
complete nucleotide sequence of the integrant was determined, revealing concatemerization of 11 subgenomic fragments in either orientation, as
represented in Fig. 1. Additional, interposed fragments were probably
of cellular origin since they exhibited no similarity to any WHV
sequence. An alignment of the subgenomic fragments with the full-length
WHV genome is presented in Fig. 1A. Most of the X gene was contained in
the 5' segment, but a C-terminal 33-nucleotide truncation precluded
functionality (22), as verified in a transactivation assay
of the simian virus 40 early and N-myc2 promoters performed
as described previously (8) (data not shown). The presence
of five copies of the We2 activator element in the central region
(coordinates 1740 to 1870 of the WHV genome, as defined in reference
12) was remarkable. Two copies were full-length, while the remaining three were truncated of the external HNF4 binding
site (HNF4b [12]). Two segments ending precisely at the same position (nucleotide 1792) were juxtaposed in a back-to-back configuration, gathering two HNF1 and two HNF4 binding sites within a
100-bp region (Fig. 1B). The W2260 woodchuck was experimentally infected at birth with serum containing WHV subtype 7 (WHV-7) (31). Inspection of the sequence at diagnostic positions
confirmed the WHV-7 subtype origin of the 2260T1 viral integrant.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
WHV sequences integrated in the 2260T1 tumor contain We1
and multiple copies of We2. (A) Fragmented representation of the 2260T1
viral integrant. Shown at the top is a physical and genetic map of the
WHV genome linearized at the BglII site, numbered according
to reference 15. Restriction sites for enzymes used
in the initial mapping of the 2260T1 integrant are indicated. Viral
genes are represented as arrows. Hatched box, sequences homologous in
position to the HBV enhancer I element (We1) (26); black
box, We2 element; closed circles, direct repeats (DR1 and DR2) involved
in the replication process. At the bottom is a diagram showing the
organization of integrated viral sequences as deduced from sequencing.
Viral subgenomic fragments are shown aligned with the corresponding
regions of the viral genome. They are represented from top to bottom in
an orderly manner indicating their 5'-to-3' positions within the
integrant. Orientations are indicated by the dotted lines and the
numbers. For reference, the N-myc2 gene maps 3' to the
2260T1 integrant in this representation. The circled numbers represent
the lengths (base pairs) of cellular sequences of unknown origin. (B)
Linear representation of the 2260T1 viral integrant. The junctions
between different viral segments or between viral and cellular
fragments are shown by vertical lines, and the numbers indicate the
nucleotide positions in the WHV genome. The arrows indicate the
direction of transcription along the viral genome. Note that the
sequence of nucleotide segment 1839 to 1848 also aligns with positions
2213 to 2222 of the viral genome, as represented in panel A and
includes half of an HNF1 binding site (12).
|
|
Transcription of integrated hepadnavirus sequences from the strong
preS2/S promoter has been previously observed in a number of woodchuck
and human liver tumors (25, 30) and can lead to the
synthesis of a potentially oncogenic, truncated PreS2/S protein
(16). However, this promoter (18) was not
represented in the 2260T1 viral integrant. Northern blot analysis of
RNA extracted from a 2260T1 liver tumor with a WHV probe did not detect
any viral transcript (data not shown), in spite of the presence of multiple copies of the C promoter and one copy of the X promoter. Thus,
the 2260T1 viral integrant does not appear to be expressed. Examination
of the cellular genomic DNA flanking the 2260T1 viral insert in the
4.3-kb fragment analyzed failed to reveal any potential coding regions
(data not shown). In addition, running the XGRAIL program on a larger,
17-kb sequenced region of the win locus similarly did not
conclusively identify any exon (10). Thus, the 2260T1 viral
insert does not appear to exert oncogenic potential through either the
production of a viral transactivator or the local cis activation of an oncogene. Since the N-myc2 gene is
expressed at a very high level in the 2260T1 tumor (11), and
since a high density of regulatory elements was evidenced in the viral
insert, we investigated the capacity of the 2260T1 integrant to
cis activate the N-myc2 promoter.
Luciferase constructs containing either the 4.3-kb
SmaI- HindIII 2260T1 fragment or control
WHV subgenomic fragments were generated and transiently transfected in
the HepG2 human liver cell line as described previously
(12). Insertion of an N-myc2 promoter-luciferase
fragment in either orientation next to the viral sequences resulted in
constructs carrying a viral insert either in a proximal position
relative to the N-myc2 promoter or in a distal position,
outside of the transcription unit (Fig. 2A). The 2260T1 viral insert proved to be
able to potently activate the N-myc2 promoter when inserted
in a distal or in a 5'-proximal position (Fig. 2B, lines 2 and 3),
leading on average to 100-fold-induced expression levels in HepG2
cells. As mentioned above, the partial X open reading frame (ORF) found
in the insert was nonfunctional and thus did not contribute to this
effect. The strong enhancer activity of the 2260T1 integrant contrasts
with properties of the isolated We2 element, which is significantly
active only when inserted in close proximity to the promoter (Fig. 2B,
lines 6 and 7) (12). The 2260T1 viral insert therefore
exhibits bona fide enhancer properties and is a potent activator of the
N-myc2 promoter.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Enhancer activity of the 2260T1 viral integrant. (A)
Schematic representation of the constructs used in transient
transfections of HepG2 cells. N-myc2, minimal N-myc2
promoter (coordinates are relative to the transcription initiation
site, indicated by arrows); LUCIFERASE, 5'-truncated firefly luciferase
cDNA (4); SV40pA, juxtaposed fragments containing the small
intron and the polyadenylation-termination signal of the simian virus
40 genome. N-myc2 and luciferase ORFs were fused in frame
(shaded boxes). Arrows indicate inserted WHV sequences, derived either
from the 2260T1 integrant (panel B, lines 2 to 5) or from the wild-type
WHV genome (lines 6 to 11). The orientation arbitrarily defined as
"+" corresponds to fragments inserted as represented at the left of
panel B and to the natural transcriptional orientation for segments
directly isolated from the cloned WHV genome (WHV e1, e2, and e1e2).
Inserts were placed on either side of the luciferase transcription
unit, either 3' in the plus orientation (3'NT+) or 5', immediately
upstream of the N-myc2 promoter, in the minus orientation
(5'NT ). (B) Plasmids containing the inserts diagrammed on the left,
in either the 5'NT or the 3'NT+ configuration, were transfected into
subconfluent HepG2 cells together with a -galactosidase expression
vector. For each construct, luciferase activity was assayed 48 h
later and normalized to the -galactosidase activity. The values
shown are relative to those generated by the parent plasmid devoid of
the WHV insert. Shown are the averages of data from three experiments.
WHVint, 4.3-kb fragment containing the 2260T1 viral integrant;
WHVint We1, fragment obtained through truncation of WHVint at an
RsrII site; WHVe2, WHVe1, and WHVe1e2, fragments extending
from positions 887 to 1501, 1700 to 2103, and 886 to 2103 in the WHV
genome, respectively, obtained through restriction digestion of a
cloned WHV-8 genome in which the natural unique NsiI site at
position 1910 had been displaced to position 2103, where an
NsiI site is found in the related virus ground squirrel
hepatitis virus.
|
|
Further deletion mapping of the 2260T1 viral insert was carried out to
identify sequences involved in transcriptional activation. Deletion of
S gene sequences downstream of the ApaI site (Fig. 1B, 3'
end) did not affect the cis-activation properties of the insert (data not shown). In contrast, deletion of sequences upstream of
the RsrII site (Fig. 1B, 5' end) severely impaired the
activation in the WHVint
We1 construct (Fig. 2B, lines 4 and 5). A
position-independent, enhancer-like effect was still observed,
suggesting that long-range transcription-activating properties can be
conferred on We2 through multimerization. Furthermore, sequences
encompassed between positions 1136 and 1700 exhibit a striking
amplification effect on the activity of the WHVint
We1 fragment.
Sequences corresponding in position to HBV enhancer I and called We1
are contained within this segment. Although some patches of nucleotide
homology between the WHV and HBV sequences overlap with known binding
sites for different transcription factors (5), We1 sequences
by themselves did not exhibit any capacity to activate the minimal
N-myc2 promoter (Fig. 2B, lines 8 and 9). Similar data from
studies using N-myc2 promoter sequences extending up to
position
1100 (12, 27) as well as other promoters (5) were previously reported. This apparent lack of activity was previously attributed to relative deficiency, inherent in liver-derived cell lines, in WHV expression compared to HBV expression (5). However, in our transient transfection assays,
provision of both We1 and We2 sequences within a contiguous subgenomic
fragment yielded a genuine enhancer effect, as efficient in a 5'
configuration as in a 3' configuration (Fig. 2B, lines 10 and 11) and
reaching levels close to those of the WHVint
We1 construct. Although
the X ORF is also included within this WHV fragment, previous
investigations demonstrated that the contribution of X transactivation
to the apparent cis-activation effect was not significant
(12, 27). Thus, although inactive in direct cis
activation on its own, the We1 element was shown here to potentiate the
activity of We2, either in a single-copy construct by conferring
long-range activation properties or in a naturally occurring viral
insertion by amplifying the enhancer effect of multiple, concatemerized
We2 copies. This peculiar form of cooperativity between We1 and We2
is reminiscent of the reported synergy between enhancers I and II of
HBV (23). It is also analogous to previously described
properties of the RFX binding site found within HBV enhancer I, a
crucial enhancer element that acts only via interaction with a second
enhancer element exhibiting a genuine transcriptional activation
capacity (6). Further studies are needed to address whether
the amplifier property of We1 is specific to We2 or it can affect other
transcriptional activator elements.
To investigate the enhancer capacity of the 2260T1 viral integrant over
large distances, constructs that carry artificially abutted
N-myc2 genes and portions of the win locus,
derived either from the rearranged allele of tumor 2260T1 or from a
wild-type allele, were generated (Fig.
3A, constructs b,
c, and d). Plasmids containing only the
N-myc2 gene (construct a), N-myc2
ligated to the same 4.3-kb viral-integrant-encompassing fragment as
that inserted in the WHVint luciferase construct (construct
e), or random 16-kb woodchuck genomic DNA fragments
(constructs f, g, and h) were also
created as controls. After transient transfection of HepG2 cells, the
production of faithfully initiated N-myc2 transcripts was
assessed by RNase mapping with a probe encompassing the
N-myc2 transcription start site (13) (Fig. 3B).
An RNA sample isolated from an N-myc2-expressing woodchuck
liver tumor and a 1/10 dilution thereof were analyzed in parallel as
controls. Similar levels of N-myc2 RNA were observed on
transfection of constructs d and e, and these
levels were much higher than those produced from construct a
(Fig. 3B, compare lanes 3 and 4, 9 and 10, and 11 and 12). In construct
d, viral sequences are separated from the N-myc2
promoter by 13 kb of win sequence in one direction and by 7 kb of DNA in the other direction due to the circular nature of the
transfected plasmids. These results suggest that the 2260T1 viral
integrant enhances N-myc2 expression from a distance as well
as it does when inserted in close proximity to the promoter.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 3.
Enhancer activity of the 2260T1 viral integrant over
large distances and absence of intrinsic regulatory activity for the
win locus in transient transfection. (A) Schematic
representations of the constructs used in transient transfections of
HepG2 cells. The DNA fragments represented were inserted in pBluescript
KS+ (Stratagene). For construct a, the 3.2-kb
HindIII insert containing the N-myc2 gene is
represented as a thick black line, with the region showing homology to
N-myc exons designated by an open box and the
N-myc2 ORF designated by a shaded box. This fragment
includes all the regulatory elements of N-myc2 identified to
date (13). It is present as a NotI insert in each
construct, only the additional sequences of which will be described
subsequently. Construct b is a 16.7-kb region of the
wild-type (WT) win locus encompassing the majority of
characterized WHV integration sites in win (10).
It is the insert from a phage isolated from the 134TA genomic library
(11) and is derived from the unrearranged win
allele as confirmed by the independent isolation of overlapping clones
from different libraries (10). Construct c is a
13.2-kb BglII fragment of the wild-type win
locus, isolated from phage 134TA.1 (11); constructs
b and c overlap in a 4.7-kb region containing the
WHV integration site of tumor 2260T1. Construct d consists
of the same region of win as that in construct c
but was isolated from a rearranged allele of tumor 2260T1 and thus
contains the viral integrant (16.15 kb) (11). Construct
e carries the same insert as the luciferase construct
WHVint, a 4.3-kb SmaI-HindIII fragment
excised from insert d. For constructs f,
g, and h, a random population of phages from the
134TA genomic library was grown and their inserts were isolated and
subcloned. Three clones which do not contain any NotI
restriction sites were randomly chosen, and these inserts could thus be
assumed to represent random woodchuck genomic sequence. They are
approximately 16 kb long. Details of the construction strategies are
available upon request. (B) Constructs were transiently transfected in
subconfluent HepG2 cells together with a -galactosidase expression
vector, and total RNA were prepared as described previously
(12). RNAs were analyzed by RNase mapping, using a probe
encompassing the N-myc2 transcription start site and RNase
T2 as described previously (12, 13). Normalization of the
input quantity was done taking into account the corresponding
-galactosidase activity. Variations in transfection efficiency did
not exceed twofold. Lanes: MW, molecular size markers (in nucleotides);
P, N-myc2 antisense RNA probe, unprocessed; a to h,
transfected constructs, as indicated at the right of panel A
(preparative transfections were performed in duplicate, and the
corresponding RNase mapping products were run in consecutive lanes);
liver tumor, 0.1 µg (lane 13) or 1 µg (lane 14) of RNA prepared
from an N-myc2-expressing woodchuck liver tumor. Faint
signals corresponding to faithfully initiated N-myc2
transcripts, visible in lanes 3, 4, 19, and 20, were more readily
detected after longer exposures.
|
|
In contrast, RNAs derived from each of the other constructs were either
barely detectable (Fig. 3B, lanes 3, 4, 19, and 20) or could not be
detected at all (lanes 5 to 8 and 15 to 18). In this assay, the
win locus does not behave differently from two randomly
chosen woodchuck genomic loci and thus does not seem endowed with
transcriptional regulatory properties. The possibility that small
plasmids might transfect more effectively than large ones could account
for the fact that N-myc2 transcripts are detected on
transfection of construct a but not of constructs
b, c, f, and g.
Alternatively, including large genomic DNA fragments in plasmids might
facilitate the assembly of a chromatin-like structure and lead to gene
repression in transient transfections. In this hypothesis, part of the
mechanism of N-myc2 activation by viral sequences in
construct d would consist of antirepression, and the faint
signal associated with control construct h might also be
accounted for by specific alleviation of such a repression phenomenon.
Collectively, these results support a model in which sequences of the
wild-type win locus are neutral with respect to
N-myc2 transcriptional regulation. Viral sequences might be
found preferentially integrated at the win locus in
woodchuck liver tumors either due to increased local accessibility or
because the high-order chromatin organization of the chromosomal domain
facilitates interaction between integrated viral enhancers and the
N-myc2 promoter over a 155- to 185-kb distance.
Additional viral sequences integrated into the win locus in
woodchuck liver tumors were further analyzed by Southern blotting with
subgenomic WHV probes. Preliminary characterizations (11) allowed the selection of three woodchuck liver tumors (50TB, 257T1, and
223T5) from a panel of 56 samples by the following two criteria: (i)
they displayed a single viral integrant, as revealed by detection of a
single high-molecular-weight band hybridizing to a full-length WHV
probe in tumor DNA digested with PvuII (an enzyme that does not cut in the viral genome) (Fig. 4A,
lanes 1 to 3); and (ii) the viral integrants mapped at the
win locus without major rearrangement of the surrounding
cellular DNA (10, 11). Each of these three viral integrants
was revealed by both We1 and We2 probes, which span regions 1158 to
1478 and 1700 to 1910 of the viral genome, respectively (Fig. 4B and C,
lanes 1 to 3). A tumor DNA harboring at least five integrants
displaying differential hybridization with either probe was loaded in
lanes 4 as a specificity control. Furthermore, digestion of tumor DNA
with restriction enzymes that cut once in the WHV genome but not in the
nucleotide 1700 to 1910 fragment (HindIII,
NsiI, or XbaI) yielded at least two
We2-hybridizing fragments in each case (Fig. 4D, lanes 1 to 3, and data
not shown). Thus, at least two copies of the We2 element were present
in each of the three integrants analyzed. These data suggest that
multimerization of We2, which can produce a potent enhancer effect, may
be commonly encountered in viral sequences integrated at the
win locus. These cases are reminiscent of rearrangements
with internal duplications of various lengths in retroviral long
terminal repeats of proviruses isolated from tumors induced by weakly
pathogenic retroviruses. These structures exhibit enhancer activity, in
contrast to the corresponding wild-type long-terminal repeats, and they
appear to be selected during tumorigenesis owing to their direct
involvement in oncogene cis activation (1, 19).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
Single viral integrants at the win locus in
woodchuck liver tumors contain We1 and multiple copies of We2. Southern
blot analysis of genomic DNA from tumors 50TB, 257T1, 223T5, and 223T6
was performed as described previously (11). The 50TB, 257T1,
and 223T5 tumors each contain a single viral integrant inserted at the
win locus. The 223T6 tumor, which harbors multiple viral
integrations displaying differential hybridization with the probes used
here, is shown as a hybridization control. Genomic DNA was digested
with PvuII (panels A to C), HindIII (panel D,
lanes 1 and 2), or XbaI (panel D, lanes 3 and 4). The probes
used for hybridization are indicated below the panels. The full-length
WHV probe (A) and the We1 probe (positions 1178 to 1478) (B) were
obtained by random priming with the cloned WHV-8 genome as a template.
The We2 template for random priming (positions 1700 to 1910) (C and D)
was generated by self-ligation of a WHV nucleotide 1700 to 1910 PCR
fragment with BamHI and BglII cohesive ends,
digestion by BamHI and BglII to rehydrolyze
head-to-head ligations, and purification of trimeric structures. Probe
stripping for sequential hybridization was achieved through two 15-min
incubations of the Hybond-N+ membrane (Amersham) in 0.4 N NaOH at room
temperature followed by two 15-min neutralizations in 50 mM sodium
phosphate buffer, pH 6.5. Complete elimination of the signal was
verified by using a PhosphorImager (Molecular Dynamics). The positions
of size markers and of WHV genome and replicative intermediates are
indicated.
|
|
We previously described the presence of We1 and/or We2 sequences in a
large majority of WHV-integrated sequences (31), and about
25% of the viral integrations involved in N-myc2 activation overlap with either We1 or We2 sequences in an exclusive fashion (10). The data presented here lend further support to the
existence of two independent regulatory elements in WHV that can
trigger N-myc2 transcription at the roots of the
hepatocarcinogenesis process. We2, which overlaps with sequences
upstream of the WHV C promoter, was recently characterized as a strong,
positively acting regulatory element that nonetheless exhibits a
minimal enhancer capacity on the N-myc2 promoter (12,
27). Here we have shown that We2 can naturally acquire
distance-independent properties upon multimerization in the integrated
state. We1 sequences, whose role remains elusive so far, are seemingly
able to amplify the activity of adjacent transcriptional activator
elements. It is conceivable that We1 synergizes with genuine or cryptic
cellular activator elements lying in the vicinity of the viral
integrant to activate the N-myc2 promoter independently of
We2. Two alternative mechanisms can be envisioned to account for the
amplifier function of We1. We1 may somehow stabilize physical
interactions between factors bound within the activator element and at
the N-myc2 promoter; alternatively, We1 may alleviate a
negative control imposed on the N-myc2 promoter and confer
permissiveness to direct transcriptional activation as recently
reported for other enhancers (29). We do not formally
exclude the possibility that We1 is additionally endowed with
more-classical transcriptional activation properties that were
deficient in the reported experimental contexts (5, 12, 27)
but might be detected in a more physiological system which remains to
be elaborated. However, our study provides a preliminary framework for
future dissection of the We1 sequences in order to identify factors
responsible for the described amplifier activity of We1. The
combination of multimerized We2 sequences with We1 observed in four
viral integrants at the win locus can generate impressive
enhancer effects. Expression levels from the N-myc2 promoter
thereby activated can be further increased on cooperation of
trans-acting pathways (8), and both mechanisms might synergize in stimulating oncogene transcription in woodchuck livers chronically infected with WHV.
 |
ACKNOWLEDGMENTS |
We thank Antonio Ponzetto for the gift of the 2260T1 tumor and
Yosef Shaul for stimulating discussions.
This work was supported by the Pasteur-Weizmann Joint Research Program.
 |
FOOTNOTES |
*
Corresponding author. Present address: CNRS UMR 49, Ecole Normale Supérieure de Lyon, 46 Allée d'Italie, 69634 Lyon Cedex 07, France. Phone: 33-4 72 72 84 53. Fax: 33-4 72 72 86 86. E-mail: Genevieve.Fourel{at}ens-lyon.fr.
 |
REFERENCES |
| 1.
|
Athas, G. B.,
P. Lobelle-Rich, and L. S. Levy.
1995.
Function of a unique sequence motif in the long terminal repeat of feline leukemia virus isolated from an unusual set of naturally occurring tumors.
J. Virol.
69:3324-3332[Abstract].
|
| 2.
|
Beasley, R. P.,
C. C. Lin,
L. Y. Hwang, and C. S. Chien.
1981.
Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan.
Lancet
ii:1129-1133.
|
| 3.
|
Buendia, M. A.
1994.
Animal models for hepatitis B virus and liver cancer, p. 211-224.
In
C. Bréchot (ed.), Primary liver cancer: etiological and progression factors. CRC Press, Boca Raton, Fla.
|
| 4.
|
de Wet, J. R.,
K. V. Wood,
M. DeLuca,
D. R. Helinski, and S. Subramani.
1987.
Firefly luciferase gene: structure and expression in mammalian cells.
Mol. Cell. Biol.
7:725-737[Abstract/Free Full Text].
|
| 5.
|
Di, Q.,
J. Summers,
J. B. Burch, and W. S. Mason.
1997.
Major differences between WHV and HBV in the regulation of transcription.
Virology
229:25-35[Medline].
|
| 6.
|
Dikstein, R.,
O. Faktor,
R. Ben-Levy, and Y. Shaul.
1990.
Functional organization of the hepatitis B virus enhancer.
Mol. Cell. Biol.
10:3683-3689[Abstract/Free Full Text].
|
| 7.
|
Etiemble, J.,
C. Degott,
C. A. Renard,
G. Fourel,
B. Shamoon,
L. Vitviski-Trépo,
T. Y. Hsu,
P. Tiollais, and M. A. Buendia.
1994.
Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion.
Oncogene
9:727-737[Medline].
|
| 8.
|
Flajolet, M.,
A. Gegonne,
J. Ghysdael,
P. Tiollais,
M.-A. Buendia, and G. Fourel.
1997.
Cellular and viral trans-acting factors modulate N-myc2 promoter activity in woodchuck liver tumors.
Oncogene
15:1103-1110[Medline].
|
| 9.
|
Fourel, G.
1994.
Genetic and epigenetic alterations of gene expression in the course of hepatocarcinogenesis, p. 297-343.
In
F. Tronche, and M. Yaniv (ed.), Liver gene expression. R. G. Landes Company, Austin, Tex.
|
| 10.
| Fourel, G. Unpublished data.
|
| 11.
|
Fourel, G.,
J. Couturier,
Y. Wei,
F. Apiou,
P. Tiollais, and M. A. Buendia.
1994.
Evidence for long-range oncogene activation by hepadnavirus insertion.
EMBO J.
13:2526-2534[Medline].
|
| 12.
|
Fourel, G.,
F. Ringeisen,
M. Flajolet,
F. Tronche,
M. Pontoglio,
P. Tiollais, and M.-A. Buendia.
1996.
The HNF1/HNF4-dependent We2 element of woodchuck hepatitis virus controls viral replication and can activate the N-myc2 promoter.
J. Virol.
70:8571-8583[Abstract].
|
| 13.
|
Fourel, G.,
C. Transy,
B. C. Tennant, and M. A. Buendia.
1992.
Expression of the woodchuck N-myc2 retroposon in brain and in liver tumors is driven by a cryptic N-myc promoter.
Mol. Cell. Biol.
12:5336-5344[Abstract/Free Full Text].
|
| 14.
|
Fourel, G.,
C. Trépo,
L. Bougueleret,
B. Henglein,
A. Ponzetto,
P. Tiollais, and M. A. Buendia.
1990.
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours.
Nature
347:294-298[Medline].
|
| 15.
|
Galibert, F.,
T. N. Chen, and E. Mandart.
1982.
Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence.
J. Virol.
41:51-65[Abstract/Free Full Text].
|
| 16.
|
Kekulé, A. S.,
U. Lauer,
M. Meyer,
W. H. Caselmann,
P. H. Hofschneider, and R. Koshy.
1990.
The pre-S2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator.
Nature
343:457-461[Medline].
|
| 17.
|
Marion, P. L.,
M. J. Van Davelaar,
S. S. Knight,
F. H. Salazar,
G. Garcia,
H. Popper, and W. S. Robinson.
1986.
Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus.
Proc. Natl. Acad. Sci. USA
83:4543-4546[Abstract/Free Full Text].
|
| 18.
|
Möröy, T.,
J. Etiemble,
C. Trépo,
P. Tiollais, and M. A. Buendia.
1985.
Transcription of woodchuck hepatitis virus in the chronically infected liver.
EMBO J.
4:1507-1514[Medline].
|
| 19.
|
Morrison, H. L.,
B. Soni, and J. Lenz.
1995.
Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
J. Virol.
69:446-455[Abstract].
|
| 20.
|
Popper, H.,
L. Roth,
R. H. Purcell,
B. C. Tennant, and J. L. Gerin.
1987.
Hepatocarcinogenicity of the woodchuck hepatitis virus.
Proc. Natl. Acad. Sci. USA
84:866-870[Abstract/Free Full Text].
|
| 21.
| Renard, C.-A., G. Fourel, and M.-A.
Buendia. Unpublished data.
|
| 22.
|
Runkel, L.,
M. Fischer, and H. Schaller.
1993.
Two-codon insertion mutations of the HBx define two separate regions necessary for its trans-activation function.
Virology
197:529-536[Medline].
|
| 23.
|
Su, H., and J. K. Yee.
1992.
Regulation of hepatitis B virus gene expression by its two enhancers.
Proc. Natl. Acad. Sci. USA
89:2708-2712[Abstract/Free Full Text].
|
| 24.
|
Summers, J.,
J. M. Smolec, and R. Snyder.
1978.
A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks.
Proc. Natl. Acad. Sci. USA
75:4533-4537[Abstract/Free Full Text].
|
| 25.
|
Terris, B.,
A. Marchio,
M.-G. Mattei,
E. Fagan,
A. Lol,
P. Tiollais, and A. Dejean.
1992.
Expression anormale de séquences du virus de l'hépatite B intégrées dans des carcinomes hépatocellulaires humains.
Gastroenterol. Clin. Biol.
16:511-517[Medline].
|
| 26.
|
Trujillo, M. A.,
J. Letrovsky,
H. F. Maguire,
M. Lopez-Cabrera, and A. Siddiqui.
1991.
Functional analysis of a liver-specific enhancer of the hepatitis B virus.
Proc. Natl. Acad. Sci. USA
88:3797-3801[Abstract/Free Full Text].
|
| 27.
|
Ueda, K.,
Y. Wei, and D. Ganem.
1996.
Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II.
Virology
217:413-417[Medline].
|
| 28.
|
Ueda, K.,
Y. Wei, and D. Ganem.
1996.
Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.
J. Virol.
70:4714-4723[Abstract].
|
| 29.
|
Walters, M. C.,
W. Magis,
S. Fiering,
J. Eidemiller,
D. Scalzo,
M. Groudine, and D. I. K. Martin.
1996.
Transcriptional enhancers act in cis to suppress position-effect variegation.
Genes Dev.
10:185-195[Abstract/Free Full Text].
|
| 30.
|
Wei, Y.,
J. Etiemble,
C. A. Renard,
P. Tiollais, and M.-A. Buendia.
1996.
Unusual activation of the integrated preS1 promoter of woodchuck hepatitis virus in a liver tumor.
J. Gen. Virol.
77:177-182[Abstract/Free Full Text].
|
| 31.
|
Wei, Y.,
G. Fourel,
A. Ponzetto,
M. Silvestro,
P. Tiollais, and M.-A. Buendia.
1992.
Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors.
J. Virol.
66:5265-5276[Abstract/Free Full Text].
|
J Virol, July 1998, p. 6175-6180, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Connolly, E., Melegari, M., Landgraf, P., Tchaikovskaya, T., Tennant, B. C., Slagle, B. L., Rogler, L. E., Zavolan, M., Tuschl, T., Rogler, C. E.
(2008). Elevated Expression of the miR-17-92 Polycistron and miR-21 in Hepadnavirus-Associated Hepatocellular Carcinoma Contributes to the Malignant Phenotype. Am. J. Pathol.
173: 856-864
[Abstract]
[Full Text]
-
Ren, S., Johnston, J. S., Shippen, D. E., McKnight, T. D.
(2004). TELOMERASE ACTIVATOR1 Induces Telomerase Activity and Potentiates Responses to Auxin in Arabidopsis. Plant Cell
16: 2910-2922
[Abstract]
[Full Text]